News Overview

February 2, 2012
Research initiative honored in Germany-wide competition
Bayer CO2 project among best ideas for the future
» more
January 27, 2012
Milestone for stacked insect-resistant, herbicide-tolerant cotton
Bayer CropScience’s TwinLink® cotton technology receives full authorization in the US
» more
January 27, 2012
“Sustainability Yearbook 2012” listing globally top performers presented in Davos:
Bayer rated the most sustainable German company in its sector
» more
January 20, 2012
Construction starts at Chempark Leverkusen:
Bayer MaterialScience builds multipurpose plant for coating raw materials
» more
January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
» more
January 18, 2012
Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
» more
December 29, 2011
Not intended for U.S. and UK Media - Submission in New Indication:
Bayer’s Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
» more
December 22, 2011
Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
» more
December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
» more
December 19, 2011
For use outside the US and UK only
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
» more
December 19, 2011
Employees donate over EUR 300,000 and company contributes a further EUR 400,000:
Bayer foundation provides EUR 700,000 for construction of children care facility in Japanese earthquake area
» more
December 19, 2011
Awards from the Bayer Science & Education Foundation:
Bayer Early Excellence in Science Award 2011: EUR 30,000 for young research scientists
» more
December 15, 2011
Settlement agreements with U.S. long-grain rice growers have taken effect
» more
December 14, 2011
For use outside the US and UK only
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
» more
December 9, 2011
Not intended for U.S. and UK media: Bayer’s drospirenone-containing combination oral contraceptives:
FDA Advisory Committees affirm positive benefit-risk profile and recommend an update of US labels to reflect information from available studies
» more
November 28, 2011
Not intended for U.S. and UK Media
Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China
» more
November 22, 2011
Bayer HealthCare and the Association of German Medical Journalists honor outstanding medical journalism for the ninth time
2010 European Journalists' Prize goes to Dr. Britta Julia Dombrowe and John A. Kantara
» more
November 16, 2011
“Perspective on Growth in Asia”
Bayer plans further expansion in Asia
» more
06:55 min.
November 13, 2011
Not intended for U.S. and UK Media: Secondary Prevention of Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Meets Primary Efficacy Endpoint and Shows Significant Reduction in Mortality in Major ACS Study
» more
November 4, 2011
Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
» more
more News
http://www.bayer.com/en/News-List.aspx

Copyright © Bayer AG

Special Interest

Print page

Search

Search
Press Newsletter
Last updated: February 2, 2012
Copyright © Bayer AG
×